24 May 2018 Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin's Lymphoma
24 May 2018 Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
23 May 2018 F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
23 May 2018 Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
23 May 2018 Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform
23 May 2018 Apogenix Provides Update on Clinical Development of Asunercept
23 May 2018 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial
23 May 2018 Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration
23 May 2018 Efficacy and safety of Cytotect® CP was demonstrated in patients after stem cell transplantation
22 May 2018 CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-2029, a CD71-Directed Probody Therapeutic
22 May 2018 FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
22 May 2018 Genentech’s HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds by 96 Percent Compared to No Prophylaxis in Phase III Haven 3 Study in Hemophilia A Without Factor VIII Inhibitors
18 May 2018 Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
17 May 2018 Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus
17 May 2018 Innovent Biologics Announces the Study Result of its Anti-PD-1 Antibody in Hodgkin Lymphoma
17 May 2018 Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
17 May 2018 Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
17 May 2018 Preliminary data from a Phase I dose escalation and expansion study of monalizumab and Imfinzi® (durvalumab) show anti-tumor activity in colorectal cancer patients
17 May 2018 Phase III IMpower150 Study Showed Genentech's TECENTRIQ and Avastin Plus Carboplatin and Paclitaxel Helped People With a Specific Type of Metastatic Lung Cancer Live Significantly Longer Compared to Avastin Plus Carboplatin and Paclitaxel
16 May 2018 CIMZIA® (certolizumab pegol) is The First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
16 May 2018 Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
16 May 2018 GT Biopharma Announces Update to OXS-3550 IND Filing, Its Most Advanced Tri-specific Killer Engager
16 May 2018 Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
15 May 2018 Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
15 May 2018 Oncternal Opens its CIRLL Study, a Combination Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up